CORRECTING AND REPLACING -- MAKO Surgical Corp. Announces Multi-System Order From Health Management Associates
March 30 2011 - 5:47PM
In a release issued earlier today by MAKO Surgical Corp.
(Nasdaq:MAKO), the company Health Management Associates, Inc.
(NYSE:HMA) was incorrectly referred to as "Hospital Management
Associates" in the headline and first paragraph. The entire
corrected release follows:
MAKO Surgical Corp. (Nasdaq:MAKO), a medical device company that
markets both its RIO® Robotic Arm Interactive Orthopedic surgical
platform and proprietary RESTORIS® implants for minimally invasive
orthopedic procedures known as MAKOplasty®, today announced receipt
of a binding commitment for the establishment of eleven new
MAKOplasty sites from Health Management Associates, Inc.
(NYSE:HMA), a premier operator of acute care hospitals primarily in
the southeast and southwest areas of non-urban America. It is
expected that these MAKOplasty sites will be established over the
course of 2011.
"We are encouraged by the strengthening of our partnership with
HMA and their increased commitment to establish MAKOplasty as an
integral part of their hospitals' orthopedic programs," said
Maurice R. Ferre, M.D., President and Chief Executive Officer of
MAKO. "This multi-system order represents the binding commitment to
purchase RIO systems that were anticipated in our 2011 plan,
allowing us to confidently reaffirm our previously announced annual
guidance of 40 to 46 systems."
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets
both its RIO® Robotic Arm Interactive Orthopedic system and its
proprietary RESTORIS® knee implants for a minimally invasive
orthopedic procedure called knee MAKOplasty®. The MAKO RIO is a
surgeon-interactive tactile surgical platform that incorporates a
robotic arm and patient-specific visualization technology, and
prepares the knee joint for the insertion and alignment of MAKO's
resurfacing RESTORIS implants through a minimal incision. The
FDA-cleared and CE Marked RIO system allows surgeons to provide
precise, consistently reproducible tissue-sparing, bone resurfacing
for a large, yet underserved, patient population suffering from
early to mid-stage osteoarthritic knee disease. MAKO has an
intellectual property portfolio of more than 250 owned or licensed
patents and patent applications relating to the areas of robotics,
haptics, computer assisted surgery and implants. Additional
information can be found at www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements related to expectations,
goals, plans, objectives and future events. MAKO intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Reform Act of 1995. In some cases, forward-looking statements can
be identified by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing" or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. These statements are based on the current
estimates and assumptions of our management as of the date of this
press release and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause actual
results to differ materially from those indicated by
forward-looking statements, many of which are beyond MAKO's ability
to control or predict. Such factors, among others, may have a
material adverse effect on MAKO's business, financial condition and
results of operations and may include the potentially significant
impact of a continued economic downturn or delayed economic
recovery on the ability of MAKO's customers to secure adequate
funding, including access to credit, for the purchase of MAKO's
products or cause MAKO's customers to delay a purchasing decision,
changes in competitive conditions and prices in MAKO's markets,
unanticipated issues relating to intended product launches,
decreases in sales of MAKO's principal product lines, any
unanticipated issues associated with fulfilling MAKO's obligations
under the HMA binding arrangement, increases in expenditures
related to increased or changing governmental regulation or
taxation of MAKO's business, unanticipated issues in securing
regulatory clearance or approvals for new products or upgrades or
changes to MAKO's current products, the impact of the recently
enacted United States healthcare reform legislation on hospital
spending, reimbursement, and the taxing of medical device
companies, loss of key management and other personnel or inability
to attract such management and other personnel and unanticipated
intellectual property expenditures required to develop, market, and
defend MAKO's products. These and other risks are described in
greater detail under Item 1A, "Risk Factors," in MAKO's annual
report on Form 10-K for the year ended December 31, 2010 filed with
the Securities and Exchange Commission on March 10, 2011. Given
these uncertainties, undue reliance should not be placed on these
forward-looking statements. MAKO does not undertake any obligation
to release any revisions to these forward-looking statements
publicly to reflect events or circumstances after the date of this
press release or to reflect the occurrence of unanticipated
events.
"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo,
whether standing alone or in connection with the words "MAKO
Surgical Corp." are trademarks of MAKO Surgical Corp.
CONTACT: Investors:
MAKO Surgical Corp.
Susan M. Verde
954.628.0749
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mako Surgical Corp. (MM) (NASDAQ:MAKO)
Historical Stock Chart
From Jul 2023 to Jul 2024